AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11292151 — intervention group
Group type: EXPERIMENTAL
Intervention: Virosome subunit vaccine (v-SUV)
Number of subjects: 635
Study 11292151 — intervention group
Group type: COMPARATOR
Intervention: Whole virus vaccine (WVV)
Number of subjects: 635
Study 9389880 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFA) in the form of capsules and margarine
Number of subjects: 40
Study 9389880 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 40
Study 7910819 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirbuterol (400 micrograms)
Number of subjects: 14
Study 7910819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2467091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg b.i.d.)
Number of subjects: 444
Study 2467091 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg b.i.d.)
Number of subjects: 444
Study 29099926 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable functional appliances (Bionator or Activator) followed by full-fixed appliances
Number of subjects: 46
Study 29099926 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepubertal Class II treatment with removable functional appliances
Number of subjects: 46
Study 29099926 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated Class II malocclusion)
Number of subjects: 46
Study 27195073 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise for 24 weeks
Number of subjects: 100
Study 27195073 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary participants)
Number of subjects: 100
Study 25038853 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of chest CT in continuous smokers
Number of subjects: 1990
Study 25038853 — intervention group
Group type: COMPARATOR
Intervention: Visual assessment of chest CT in former smokers
Number of subjects: 1990
Study 25038853 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of chest CT for interstitial abnormalities
Number of subjects: 1990
Study 22952172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 58
Study 22952172 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGBP)
Number of subjects: 58
Study 22952172 — intervention group
Group type: EXPERIMENTAL
Intervention: SG
Number of subjects: 58
Study 22952172 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGBP
Number of subjects: 58
Study 20940381 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (maintain hematocrit ≥30%)
Number of subjects: 502
Study 20940381 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (maintain hematocrit ≥24%)
Number of subjects: 502
Study 19549433 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatropin inhalation powder (SIP)
Number of subjects: 26
Study 19549433 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneously injected rhGH (Hsc)
Number of subjects: 26
Study 19549433 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 26
Study 16168780 — intervention group
Group type: EXPERIMENTAL
Intervention: Early radiotherapy (54 Gy in fractions of 1.8 Gy)
Number of subjects: 314
Study 16168780 — intervention group
Group type: COMPARATOR
Intervention: Control (deferred radiotherapy until progression)
Number of subjects: 314
Study 11879237 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular Adsorbents Recycling System (MARS) treatment
Number of subjects: 103
Study 9880443 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (L‐GG)
Number of subjects: 204
Study 9880443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 7721639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment quality control review of radiation therapy fields
Number of subjects: 625
Study 7721639 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment quality control review
Number of subjects: 625
Study 1741738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (individual or group)
Number of subjects: 19
Study 1741738 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 19
Study 1741738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (individual therapy)
Number of subjects: 19
Study 1741738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (group therapy)
Number of subjects: 19
Study 6807240 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacycline (PGI2) infusion at 25 ng/Kg/min before Heparin, then 50 ng/Kg/min during bypass
Number of subjects: 28
Study 6807240 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacycline (PGI2) infusion
Number of subjects: 28
Study 6807240 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 28
Study 30932252 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home respiratory polygraphy
Number of subjects: 113
Study 30932252 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring with nasal airflow signal present
Number of subjects: 113
Study 30932252 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring without nasal airflow signal
Number of subjects: 113
Study 30932252 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring with RIP flow
Number of subjects: 113
Study 29121268 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic score for schizophrenia (SCZ)
Number of subjects: 2586
Study 29121268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-trait meta-GWAS
Number of subjects: 2586
Study 27657546 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene Blue Injection
Number of subjects: 102
Study 27657546 — intervention group
Group type: COMPARATOR
Intervention: Hookwire Insertion
Number of subjects: 102
Study 23656594 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk with L. paracasei SD1
Number of subjects: 30
Study 23656594 — intervention group
Group type: COMPARATOR
Intervention: Milk without L. paracasei SD1 (Control)
Number of subjects: 30
Study 22056151 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetite rating (very good to very poor) on dialysis days
Number of subjects: 1846
Study 22056151 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetite rating (very good to very poor) on nondialysis days
Number of subjects: 1846
Study 22056151 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine
Number of subjects: 1846
Study 22056151 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor appetite on dialysis days
Number of subjects: 1846
Study 22056151 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor appetite on nondialysis days
Number of subjects: 1846
Study 19172517 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg once daily (group A)
Number of subjects: 191
Study 19172517 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1800 mg daily (group B)
Number of subjects: 191
Study 19172517 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of pitavastatin and EPA (group C)
Number of subjects: 191
Study 19172517 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (normolipidemic patients)
Number of subjects: 191
Study 17993028 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Vivid White whitening dentifrice used twice daily
Number of subjects: 52
Study 17993028 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Vivid White Night used at night and Crest Cavity Protection used in the morning
Number of subjects: 52
Study 17993028 — intervention group
Group type: COMPARATOR
Intervention: Control power toothbrush with cavity protection dentifrice
Number of subjects: 52
Study 16848361 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy after radical prostatectomy
Number of subjects: 0
Study 16848361 — intervention group
Group type: COMPARATOR
Intervention: Hormonal therapy alone
Number of subjects: 0
Study 16848361 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy (combined with prostatectomy and radiotherapy)
Number of subjects: 0
Study 14693305 — intervention group
Group type: EXPERIMENTAL
Intervention: Stevioside (500 mg, 3 times daily for 2 years)
Number of subjects: 174
Study 14693305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 10978399 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 (60 mg/day)
Number of subjects: 36
Study 10978399 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B12 (500 microg/day)
Number of subjects: 36
Study 8677658 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HES 200/0.62
Number of subjects: 12
Study 8677658 — intervention group
Group type: COMPARATOR
Intervention: 6% HES 200/0.62
Number of subjects: 12
Study 1345022 — intervention group
Group type: EXPERIMENTAL
Intervention: Apulein cream
Number of subjects: 0
Study 1345022 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone ointment
Number of subjects: 0
Study 6229920 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC+HD-MPA i.m.
Number of subjects: 76
Study 6229920 — intervention group
Group type: COMPARATOR
Intervention: FAC+HD-MPA p.o.
Number of subjects: 76
Study 6229920 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC+HD-MPA i.m. and FAC+HD-MPA p.o.
Number of subjects: 76
Study 31571296 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with oral nutritional supplements
Number of subjects: 10
Study 31571296 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 10
Study 31571296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support
Number of subjects: 10
Study 29023221 — intervention group
Group type: EXPERIMENTAL
Intervention: Active phototherapy
Number of subjects: 0
Study 29023221 — intervention group
Group type: COMPARATOR
Intervention: Sham phototherapy
Number of subjects: 0
Study 25690268 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment and diabetes education
Number of subjects: 1092
Study 25690268 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy (at screening)
Number of subjects: 1092
Study 25247985 — intervention group
Group type: EXPERIMENTAL
Intervention: Air cleaner in filtration mode
Number of subjects: 31
Study 25247985 — intervention group
Group type: COMPARATOR
Intervention: Placebo filtration mode
Number of subjects: 31
Study 22116471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive treatment, exposure treatment, or their combination with fluvoxamine
Number of subjects: 91
Study 22116471 — intervention group
Group type: COMPARATOR
Intervention: No sudden gains
Number of subjects: 91
Study 20518948 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN/LRPT (1 g) plus statin, advanced to ERN/LRPT (2 g) after 4 weeks
Number of subjects: 1216
Study 20518948 — intervention group
Group type: COMPARATOR
Intervention: Doubling the dose of statin
Number of subjects: 1216
Study 16829217 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin
Number of subjects: 508
Study 16829217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508
Study 15654576 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol 400 mg iodine/mL
Number of subjects: 22
Study 15654576 — intervention group
Group type: COMPARATOR
Intervention: iomeprol 300 mg iodine/mL
Number of subjects: 22
Study 12397697 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II type 1 receptor antagonist losartan
Number of subjects: 30
Study 12397697 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme (ACE) inhibitor enalapril
Number of subjects: 30
Study 12397697 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonist amlodipine
Number of subjects: 30
Study 12397697 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 30
Study 12397697 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 30
Study 12397697 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 30
Study 9974196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (ankle disk for 10‐15 min at all practice sessions for one 10‐month season)
Number of subjects: 237
Study 9974196 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 237
Study 8640145 — intervention group
Group type: EXPERIMENTAL
Intervention: Catalet C and Catalet D (allergen extracts)
Number of subjects: 41
Study 8640145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2301521 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted vaginal cones
Number of subjects: 69
Study 2301521 — intervention group
Group type: COMPARATOR
Intervention: Interferential therapy
Number of subjects: 69
Study 7015692 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vincristine, nitrosomethylurea, and dactinomycin
Number of subjects: 114
Study 7015692 — intervention group
Group type: COMPARATOR
Intervention: DTIC (150 mg/m2 iv days 1, 2, 3, 4, 5)
Number of subjects: 114
Study 31515419 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Qigong
Number of subjects: 126
Study 31515419 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 126
Study 31515419 — intervention group
Group type: COMPARATOR
Intervention: Control group (attention control)
Number of subjects: 126
Study 28351399 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic baths (40 °C), 2 baths per week for 4 weeks
Number of subjects: 36
Study 28351399 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (green light)
Number of subjects: 36
Study 26101239 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 4260
Study 24336671 — intervention group
Group type: EXPERIMENTAL
Intervention: Notch3 expression in placentas from patients with early-onset severe preeclampsia
Number of subjects: 0
Study 24336671 — intervention group
Group type: EXPERIMENTAL
Intervention: Notch2 expression in placentas from patients with early-onset severe preeclampsia
Number of subjects: 0
Study 24336671 — intervention group
Group type: EXPERIMENTAL
Intervention: Notch2 and Delta-like4 (Dll4) mRNA levels in placentas from patients with early-onset severe preeclampsia
Number of subjects: 0
Study 21247622 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchrovine® (two doses of PGF(2α), 7 d apart)
Number of subjects: 1297
Study 21247622 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchrovine® (chilled semen, cervical TAI at 42 h)
Number of subjects: 1297
Study 21247622 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchrovine® (chilled semen, cervical TAI at 51 or 57 h)
Number of subjects: 1297
Study 21247622 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchrovine® (intrauterine TAI at 51 or 57 h)
Number of subjects: 1297
Study 19390338 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 14
Study 17708123 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT)
Number of subjects: 129
Study 17708123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 15643648 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic treatment for anxiety
Number of subjects: 0
Study 15643648 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 11136140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-extremity flexion to extension
Number of subjects: 38
Study 11136140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-extremity extension to flexion
Number of subjects: 38
Study 11136140 — intervention group
Group type: EXPERIMENTAL
Intervention: Position 1 to Position 3 (same position)
Number of subjects: 38
Study 9602985 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel potent 5HT3 receptor antagonist
Number of subjects: 370
Study 9602985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 7798838 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 0
Study 7798838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pentoxifylline)
Number of subjects: 0
Study 3391736 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA 37.5 mg (immediate release formulation)
Number of subjects: 6
Study 31294771 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab, 0.5 mg, every 4 weeks
Number of subjects: 1561
Study 31294771 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept, 2 mg, every 4 weeks
Number of subjects: 1561
Study 31294771 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept, 0.5 mg, every 4 weeks
Number of subjects: 1561
Study 31294771 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept, 2 mg, every 8 weeks after 3 doses at 4-week intervals
Number of subjects: 1561
Study 28751662 — intervention group
Group type: EXPERIMENTAL
Intervention: L p -Adaptation method
Number of subjects: 0
Study 28751662 — intervention group
Group type: COMPARATOR
Intervention: Previous state of the art methods
Number of subjects: 0
Study 26427561 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised multi-modal physical exercise program (including behavior-oriented techniques)
Number of subjects: 0
Study 26427561 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised multi-modal physical exercise program (not including behavior-oriented techniques)
Number of subjects: 0
Study 26427561 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving any supervised intervention)
Number of subjects: 0
Study 22856681 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfilled composite (Esthet.X/Dentsply/De Trey, Prime&Bond NT/Dentsply/De Trey)
Number of subjects: 30
Study 22856681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanohybrid composite (TetricEvoCeram/Vivadent, AdheSE/Vivadent)
Number of subjects: 30
Study 22856681 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer (Dyract eXtra/Dentsply/De Trey, Xeno III Dentsply/De Trey)
Number of subjects: 30
Study 21371323 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 250
Study 21371323 — intervention group
Group type: COMPARATOR
Intervention: Paper-based intervention
Number of subjects: 250
Study 21371323 — intervention group
Group type: EXPERIMENTAL
Intervention: Email invitations
Number of subjects: 250
Study 21371323 — intervention group
Group type: COMPARATOR
Intervention: Postal invitations
Number of subjects: 250
Study 18286346 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group meeting attendance (ASGM)
Number of subjects: 46
Study 18286346 — intervention group
Group type: COMPARATOR
Intervention: No support group meeting attendance (NASGM)
Number of subjects: 46
Study 16864811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessment in hemodialysis patients
Number of subjects: 374
Study 12581930 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking and stretching/toning activity
Number of subjects: 174
Study 15210552 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniett device (self-administered 3 times daily)
Number of subjects: 62
Study 15210552 — intervention group
Group type: COMPARATOR
Intervention: Placebo Meniett device (identical but exerted no pressure)
Number of subjects: 62
Study 9949705 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition of words heard earlier
Number of subjects: 0
Study 9949705 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced quick response or secondary task while reading words
Number of subjects: 0
Study 8581453 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole-pseudoephedrine
Number of subjects: 50
Study 8581453 — intervention group
Group type: COMPARATOR
Intervention: Loratadine-pseudoephedrine
Number of subjects: 50
Study 2128892 — intervention group
Group type: EXPERIMENTAL
Intervention: CANFIT computer aided design (CAD) software
Number of subjects: 48
Study 2128892 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 48
Study 333921 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study 333921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31631570 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative intent treatment
Number of subjects: 469
Study 31631570 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative intent treatment
Number of subjects: 469
Study 31631570 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic Index (PI) variables
Number of subjects: 469
Study 31631570 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score system
Number of subjects: 469
Study 27492480 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 4
Study 27492480 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver Cirrhosis (LC)
Number of subjects: 4
Study 27492480 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Diabetes Mellitus and Liver Cirrhosis (DM and LC)
Number of subjects: 4
Study 27492480 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4
Study 25030801 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg/day)
Number of subjects: 53
Study 25030801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 23318025 — intervention group
Group type: EXPERIMENTAL
Intervention: Conners' Adult ADHD Rating Scale-Investigator Rated: Screening Version
Number of subjects: 0
Study 21050274 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 mg/kg YS
Number of subjects: 96
Study 21050274 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg/kg YS
Number of subjects: 96
Study 19065446 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Failure Clinic (HF) follow-up
Number of subjects: 163
Study 19065446 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 163
Study 17512770 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose apomorphine
Number of subjects: 40
Study 17512770 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 15496223 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil HCl 5 mg daily for 7 days + Risperidone
Number of subjects: 16
Study 15496223 — intervention group
Group type: COMPARATOR
Intervention: Donepezil HCl 5 mg daily for 7 days (Control)
Number of subjects: 16
Study 15496223 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 16